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 21 
Abstract (175 words) 22 
Background: Thyroid-associated orbitopathy (TAO) is the most common auto-23 
immune disease of the orbit. It occurs more often in patients presenting with 24 
hyperthyroidism, characteristic of Graves’ disease, but may be associated with 25 
hypothyroidism or euthyroidism. The diagnosis of TAO is based on clinical orbital 26 
features, radiological criteria and the potential association with thyroid disease. To 27 
date, there is no specific marker of the orbital disease, making the early diagnosis 28 
difficult, especially if the orbital involvement precedes the thyroid dysfunction. 29 
Summary: The goal of this review is to present the disease and combine the 30 
available data in the literature concerning investigation of TAO biomarkers.  31 
Conclusions: Despite the progress done in the understanding of TAO disease, some 32 
important pieces are still missing. Typically, for the future, major efforts have to be 33 
done in the discovery of new biomarkers, validation of the suspected candidates on 34 
multicenter cohorts with standardized methodologies and establishment of their 35 
clinical performances on the specific clinical application fields in order to improve the 36 
management of the TAO patients but also the therapeutic options and follow-up.  37 
 38 
Keywords: Biomarkers, Thyroid-Associated Orbitopathy, tears, orbital fat, blood, 39 
inflammation 40 
 41 
 42 
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 43 
 44 
Clinical significance 45 
Around 25-50% of patients with Graves’ disease develop TAO without any predictive 46 
factor. Moreover, the ocular disorder usually appears after the thyroid disease or 47 
simultaneously, but may precede it. Identifying new biomarkers of this orbital disease 48 
could help to an early diagnosis, especially if the orbital involvement precedes the 49 
thyroid dysfunction. 50 
 51 
Introduction 52 
Thyroid-associated orbitopathy (TAO), also known as thyroid eye disease or Graves’ 53 
ophthalmopathy, is an autoimmune disease affecting thyroid, orbits and skin. Despite 54 
important progress in understanding the pathophysiological mechanisms leading to 55 
the development of this disease in the orbits during the last decade, some important 56 
questions are still without any answer. The exact nature of the relationship of TAO 57 
with thyroid remains enigmatic: hyperthyroidism can be related to the development of 58 
this orbital disease but exceptions exist. In contrast, TAO can occur in hypo- or 59 
euthyroid patients. Therefore, the prediction of Graves’ evolution to TAO is difficult 60 
and limits early treatment. At cellular and molecular levels, the reason why only 61 
orbital fibroblasts (and not the other fibroblasts of the body), orbital adipose tissue 62 
and medial and inferior rectus muscles are more often affected during the disease 63 
has not been solved yet. Furthermore, the possibility to have unilateral orbital case 64 
and the great variety of clinical presentation are not understood. This last point 65 
highlights also in some cases the difficulty to properly diagnose TAO disease by 66 
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cofounding with mimicking diseases such as orbital myositis, amyloidosis, some 67 
tumors or metastatic cancer and IgG4-related diseases [1-12]. 68 
In this context, the discovery of new biomarkers that could definitively assist the 69 
physician to diagnose TAO disease as early as possible, predict prognosis and 70 
propose early and appropriate treatment will be clinically useful for improving patient 71 
management. After a brief recall of the clinical manifestations and the 72 
pathophysiology, we review where we are in the potential biomarkers reported in 73 
TAO and which vision we can have for the future. 74 
Review 75 
The natural history of TAO, without any treatment, is described as the Rundle’s curve 76 
[13-15]. Symptoms and signs of the orbital disease worsen rapidly during an initial 77 
phase, reach a maximal severity, and decrease to a plateau known as the sequellar 78 
form. The disease appears 2-6 times more frequent in young women but severe 79 
cases occur more frequently in men of more than 50 years old [16]. 80 
The manifestations of the orbital involvement are irritation and redness of the eyes 81 
and eyelids, lid tumefaction, double vision and rarely visual loss. The bilateral 82 
complete orbital examination should look for lid retraction, proptosis (exophthalmos), 83 
limitation of ocular motility, fat hypertrophy, deficit of visual acuity or color vision, the 84 
signs of corneal exposure, and signs of orbital inflammation [17-19] (Figs 1 and 2). 85 
Clinically, the challenge is to recognize the active, inflammatory phase of the orbital 86 
disease. In fact, early diagnosis and rapid introduction of the anti-inflammatory 87 
treatment, mainly steroids, improve the final outcome and reduce the functional and 88 
disfiguring sequellae of the disease [14, 20]. As in some cases the orbital 89 
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manifestations precede the thyroid dysfunction and its systemic signs [21], it seems 90 
essential to have a biomarker dedicated to the early diagnosis of the orbital disease. 91 
The detection of Thyroid stimulating hormone-receptor (TSH-Receptor) antibodies 92 
(TSH-R-Abs) may confirm the auto-immunity and the diagnosis of TAO. But these 93 
antibodies are not present in all cases [19, 22, 23]. 94 
So far, we use the clinical activity score (CAS) to determine the indication and the 95 
duration of anti-inflammatory treatment [22, 24]. We take in consideration the 96 
presence or not of pain, lid and conjunctival edema (chemosis), lid and conjunctival 97 
redness. Nevertheless, as for all the clinical scales, this one presents some 98 
limitations: CAS is based on few items, mixing different types of clinical information 99 
(inflammation versus vision worsening) and proposing only binary answers, reducing 100 
therefore the accuracy of its interpretation. Furthermore, this is a subjective scale 101 
depending therefore on the timing of the evaluation, the willingness and objectivity of 102 
the patients regarding their clinical situations and on the level of expertise of the 103 
practitioner performing the evaluation. Other scales exist including NOSPECS [25], 104 
VISA [26] and EUGOGO [27] but present also advantages and limitations and are not 105 
daily used in our hospital. 106 
In some difficult cases, the magnetic resonance imaging (MRI) could help to find out 107 
the presence of an inflammatory process. Definitely, having molecules that could 108 
efficiently complement clinical scores and observation could allow a more precise 109 
and rapid diagnosis and also limit the economic burden to useless access to imaging.  110 
All the patients with irritation, lid retraction and proptosis, should benefit of a local 111 
lubricant treatment (eye drops and ointment). In presence of orbital inflammation, 112 
some treatments such as selenium and steroids are indicated, according to the 113 
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severity [22]. The goal is to stop the inflammatory process and to improve the final 114 
outcome. In case of resistance or contraindication, low dose external radiotherapy is 115 
suggested. The immunomodulatory treatments such as Tocilizumab (Interleukin (IL)-116 
6 receptor antagonist), Teprotumumab (Insulin-like growth factor-1 (IGF-1) receptor 117 
antagonist) or Rituximab (anti-CD20) [28] seem to give promising results in resistant 118 
cases [18, 29-31].  119 
Rehabilitative surgery should be performed in patients with inactive TAO since at 120 
least six months. The main steps are orbital decompression for the reduction of 121 
proptosis, squint surgery for the treatment of muscular fibrosis and diplopia, lid 122 
lengthening and blepharoplasty for lid retraction and fat hypertrophy. 123 
The finding of specific biomarkers of TAO may serve as a predictive factor of 124 
development of TAO among patients with Graves’ disease, and may also give some 125 
information on the severity of TAO. 126 
The pathophysiology of TAO is poorly understood. Some classical risk factors 127 
including genetic predisposition, environmental factors, infection and stress, have 128 
been reported but their real impact on TAO initiation remains debated [32]. 129 
Nevertheless, some pieces of the puzzle begin to come together in the literature. 130 
B-cells, T-cells and orbital fibroblasts have been shown to be the key players of the 131 
pathological event. At the origin, T-cells are responsible for the initiation of 132 
the disease [19]. Indeed, T helper cells become activated when they 133 
recognize TSH-R peptides on antigen-presenting cells. Upon interactions 134 
with such T-cells, B-cells secrete anti-TSH-R antibodies. These antibodies 135 
lead to stimulation of both thyroid follicular cells, which produce a great 136 
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quantity of thyroid hormones, and orbital fibroblasts, which proliferate and 137 
induce orbital changes. 138 
Beside TSH-R, IGF-1 receptor (IGF-1R) was also identified as a potential targeted 139 
antigen [32-37] and it seems that the interactions between TSH-R and IGF-1R are 140 
more important than individual molecules effect [38]. Furthermore, patients can have 141 
either one or both types of auto-antibodies and alternative production of other types 142 
of auto-antibodies is not excluded. Indeed, recent studies suggested that auto-143 
antibodies against carbonic anhydrase 1 and alcohol dehydrogenase 1B had higher 144 
prevalence in orbital fat in TAO compared to controls [39].  145 
Tripartite relationships between orbital fibroblasts, B- and T-cells initiate cascades of 146 
immune and chemical reactions [40, 41] resulting in pathological situations: 147 
inflammation of the connective tissues, fibrosis and adipogenesis [32, 33]. 148 
These phenomena cause fundamental and dramatic ocular tissue remodeling. The 149 
increased volume of extraorbital muscles, induced by intensive hyaluronic acid (HA) 150 
production [42] and expansive growth of adipose tissue via activation of peroxisome 151 
proliferator activated receptor gamma (PPAR-γ) [43], leads consequently to the 152 
typical eye’s protrusion, characteristic of TAO patients. In addition, the compression 153 
of orbital tissue causes a compression of vascular structures leading to the reduction 154 
of blood flow and subsequent localized hypoxia [44]. In this context, proangiogenic 155 
factors seem to be stimulated in order to restore appropriate circulation through the 156 
formation of new vessels. 157 
 158 
Biomarkers 159 
27.06.2018               8 
 
In this context, as previously mentioned, no accurate molecular tool allows to date 160 
establishing a rapid, early and robust diagnosis of TAO or predicting the outcome or 161 
the efficiency of drug therapy. Nevertheless, the availability of these kinds of tools, 162 
objectively measurable and easily interpretable, could greatly enhance the 163 
management of TAO patients, especially those with normal thyroid function. 164 
However, over the years and regarding the increased number of publications in the 165 
biomarker field, only relatively few studies have been focused on the discovery of 166 
new biomarkers in TAO disease.  167 
The term ‘biomarker’ was officially and accurately defined 15 years ago as a single 168 
indicator “that objectively measures and evaluates normal or pathogenic biological 169 
processes” [45]. Consequently, a biomarker is not restricted to being a protein, but 170 
may be any type of specific molecular signature such as a gene, mRNA or a 171 
metabolite. Specific clinical features such as demographic and physiological 172 
parameters (age, gender, smoking status, or goiter size), imaging (thyroid volume 173 
with ultrasonography or IRM) or clinical scores (CAS, Vision, Inflammation, and 174 
Appearance (VISA)) can also be considered as objective biomarkers. However, only 175 
the molecular biomarkers will be considered here.  176 
In order to be efficient, biomarker discovery in general but also in TAO context should 177 
carefully consider the best source of samples in relation to both the clinical question 178 
and the methods of investigations. To be applicable on a large-scale, a good source 179 
of biomarkers should take into account the feasibility of sample collection and its 180 
relevance. Extremely invasive sample collection (e.g. biopsy of orbital fat or 181 
extraorbital muscles), even if it is highly specific due to the close relationship with the 182 
location of a disease, must not be taken for granted because of (i) the related 183 
discomfort and risks of secondary complications for the patient; (ii) the restricted 184 
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access for clinical diagnosis, and (iii) the great difficulty in collecting such samples 185 
from healthy control subjects. 186 
 187 
Biomarkers – hormones and antibodies - in blood of TAO patients 188 
In TAO disease, traditional biological fluids including blood and urine have been 189 
investigated. The majority of the studies rather reported principal actors of the TAO 190 
disease as potential biomarkers than discovered new candidates. Considering the 191 
dysfunction of the thyroid gland associated to TAO, the traditional circulating thyroid 192 
hormones (TSH, triiodothyronine  also known as T3 and thyroxine, called T4) used 193 
for diagnosing thyroid dysfunction or the antibodies against TSH-R (TSH-R-Abs) [22, 194 
46] or thyroid peroxidase (TPO)-Abs [47, 48], would be naively expected to be highly 195 
studied and give an interesting insight on the clinical status of the TAO patients.  196 
Thus, whatever the generation of assays used, TSH-R levels were shown to be 197 
associated to activity and severity of TAO [46, 49-51]. The new generation tests 198 
allowed to reach up to 97% sensitivity and almost 90% specificity [51]. However to 199 
date, some limitations persist for a clinical use of TSH-R in the management of TAO. 200 
The heterogeneous pattern of thyroid dysfunction in TAO patients - hyperthyroidism, 201 
euthyroidism (6 to 21% depending on the studies [52-54]), or hypothyroidism - and 202 
the fact that various other diseases [55] may disturb thyroid hormones greatly limit 203 
their clinical relevance in TAO diagnosis. Indeed, a potential interference of treatment 204 
with the TSH-R level has been suspected [56-58] and could disturb their 205 
performances in TAO prediction.  206 
In conclusion, conflicting data related to different types of generation assays and 207 
various experimental designs do not allow to defintively evaluate the clinical 208 
performance of TSH-R-Ab on TAO patients and the conditions of its routine use 209 
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remain to be clarified. In the same context, the association TPO-Ab and TAO is still 210 
questionable as different studies reported various results [47, 59-61]. 211 
 212 
Biomarkers – cytokines and others - in blood of TAO patients 213 
As the pathology is driven by an acute inflammatory event, the pro-inflammatory 214 
cytokines/chemokines including IL-1β [62], IL-6 [63], IL-10 [63], IL-8 [64], C-C 215 
chemokine ligand 20 (CCL20) [65] and IL-17 [66] have been studied. The reported 216 
data reveal an elevation of their level in the blood of TAO patients compared to 217 
control patients that could highlight a potential interest of these molecules as 218 
diagnosis markers. Furthermore, their levels seem even able to determine the stage 219 
of the disease: an active phase is characterized by a higher level of IL1β, IL6 [62] 220 
and IL-17 [66] compared to inactive phase. The data suggested also that the blood 221 
levels of some cytokines could reflect the response to treatment: patients presenting 222 
refractory TAO have higher level of IL-4, IL-6 and IL-10 than patients in remission 223 
[63]. Furthermore, patients present modified blood level of IL-16 (increase) and IL-8 224 
(decrease) after steroids treatment compared to the previous state [64, 67]. 225 
Moreover, a possible association of serum IL-10 polymorphism with incidence of 226 
TAO has been reported [68].  227 
Based on only two unique studies, controversial data exist on Interferon-γ (IFN-γ) 228 
and its potential disturbance in blood of TAO patients [62, 69]. The cytokines involved 229 
as mediators of B-cells and/or T-cells have also been largely investigated due to the 230 
key roles of these cells in the initiation and the course of the TAO disease. 231 
Interleukin-2 [68], IL-16 [67] and IL-33 [69] have been shown to be highly elevated in 232 
the blood of TAO patients compared to controls. Serum IL-33 levels were positively 233 
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correlated with T3 and T4, however negatively correlated with TSH [69]. A 234 
polymorphism of IL-2 is suggested to be associated with the disease [68].  235 
Due to their mitogenic and angiogenic properties, the potential value of growth 236 
factors has also been investigated. Serum hepatocyte growth factor (HGF) increases 237 
in TAO patients compared to control subjects and is sensitive to efficient 238 
glucocorticoids treatment. Its level decreases in response to drug administration [64]. 239 
Adhesion molecules belong to another class of molecules investigated as potential 240 
TAO markers. They play a role in cell/cell or cell/extracellular matrix interaction, 241 
activation and migration. Intercellular adhesion molecule-1 (ICAM-1) and soluble 242 
vascular cell adhesion molecule-1 (sVCAM-1) have been found elevated in the blood 243 
of TAO patients as compared to control patients but their levels seem also to be 244 
influenced by the treatment [70]. 245 
Selenium is a metabolite implicated in thyroid hormone synthesis and metabolism 246 
[71], both actions having high importance in TAO development [72]. Besides, high 247 
amounts of selenium are found in thyroid gland. In an Australian population in 2014, 248 
TAO patients showed lower levels of selenium in serum than patients suffering from 249 
Graves’ disease without eye involvement. In addition, selenium levels decrease with 250 
TAO increasing severity. The authors conclude that the lack of selenium might be an 251 
independent risk factor for TAO [72]. 252 
The potential interest of several exotic biomarkers in TAO recently emerged notably 253 
because of the use of omics strategies. Among these emerging candidates, none of 254 
them has been deeply evaluated to date but several can be mentioned for their 255 
biological functions that could be directly related to TAO disease. This is the case of 256 
osteopontin [65, 73], a multifunctional protein involved in inflammation, cell 257 
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recruitment, cell adhesion and remodeling. It is inversely correlated with TSH level 258 
and positively with T3 and T4 [73]. Another protein called cytotoxic T lymphocyte 259 
associated antigen-4 (CTLA-4), a member of the immunoglobulin superfamily, which 260 
is found on T-cell surface, negatively regulates these cells. So far, many studies have 261 
been focused on a polymorphism localized on CTLA-4 gene, as a consequence of its 262 
implication in autoimmune diseases [74-76]. Finally HLA-B8, a MHC class I cell 263 
surface receptor, has been observed in association with TAO but its role remains to 264 
be elucidated [77, 78]. 265 
Biomarkers in urine of TAO patients 266 
Urine and its components have been little investigated as potential source of 267 
biomarkers in the context of TAO. However, three compounds showed a potential 268 
promising interest and should be more studied in the future. The cotinine level, the 269 
main metabolite of nicotine used as marker of tobacco use, seems to correlate in 270 
smokers TAO patients with the level of blood TSH-R-Abs, the activity of the disease 271 
and secondary ocular complication after radioiodine treatment [79, 80]. 272 
Glycosaminoglycans (GAGs), the most abundant heteropolysaccharides, display a 273 
urinary levels 2-3 times higher in patients with the active form compared to those with 274 
the inactive form [81]. Finally, 8-hydroxy-2’-deoxyguanosine (8-OHdG) has attracted 275 
attention of scientist’s community. This metabolite is used to measure DNA damage 276 
in oxidative stress, event that was related with various ocular diseases such as TAO. 277 
High levels of 8-OHdG were found in TAO patients urine compared to control 278 
patients, and 8-OHdG level was related to CAS [82]. In short, 8-OHdG might be a 279 
good biomarker in the future to evaluate the presence of oxidative DNA damage and 280 
therefore the oxidative stress generated in TAO patients.   281 
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Biomarkers in blood and urine of TAO patients: conclusions 282 
In conclusion, these 2 common fluids usually explored for biomarker discovery seem 283 
disappointing in TAO. Several explanations could be highlighted: at this stage, only 284 
few studies focus on the same molecules and, in the main cases, the candidates are 285 
investigated not for their potential role as biomarkers but rather for their central role in 286 
the pathological events. This is particularly illustrated by the absence of clinical 287 
performances (sensitivity, specificity, positive and negative predictive values) 288 
reported in the publications. Nevertheless, with the democratization of the omics 289 
methods, we may speculate that, in a near future, new and probably unexpected 290 
biomarkers will be discovered and could offer new clinical and management 291 
strategies for TAO. 292 
Moreover, no standardized protocol is reported for the evaluation of a specific target 293 
and different clinical questions are frequently assessed with a unique cohort design 294 
decreasing the power of the analyses. Another aspect could be that the modifications 295 
of molecular levels occurring in response to this disease may be too subtle to be 296 
efficiently measured in these systemic fluids.  We assume therefore that fluids or 297 
tissues geographically close to the place of the disease (the eyes) will be more 298 
valuable. 299 
Biomarkers in orbital fat of TAO patients 300 
Exploring the orbital fat content in TAO patients is, to our point of view, highly 301 
relevant since the disease directly affects this tissue. In orbital fat, the IL-1β and IL-6 302 
levels seem to be associated with the smoker status of TAO patients [83]. Besides, a 303 
transcriptomics study performed on orbital fat reports a clear upregulation of IFN-γ in 304 
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TAO patients [84]. Transforming growth factor-β (TGF-β) and fibroblast growth factor 305 
(FGF) are elevated in the orbital fat of TAO patients and levels of these factors are 306 
correlated with the severity of the disease. In the family of growth factors, platelet-307 
derived growth factor (PDGF) is probably the most promising at this stage with a 308 
central role in the TAO pathological events. Indeed, several studies have reported its 309 
overexpression in orbital tissues of TAO patients [85-87], independently of the activity 310 
grade of TAO. In addition, specific isoforms of PDGF improve the TSH-R expression 311 
on orbital fibroblasts, amplifying the autoimmune reaction against TSH-R [85]. Drugs 312 
blocking PDGF signalling allow opening new therapeutic options [87, 88]. Finally, in 313 
vitro studies have also highlighted the adipogenic function of PDGF, able to induce 314 
the transformation of orbital fibroblasts into adipocytes [89]. This mechanism 315 
participates in the extension of orbital tissue during TAO course. Adipogenesis is also 316 
induced by IL-1β through an increase of Cyclooxygenase-2 (COX-2). This enzyme, 317 
known to modulate inflammation, is anticipated to be a central element of the active 318 
phase of TAO disease. Its mRNA and protein levels have been shown to be 319 
overexpressed in orbital fibroblasts of TAO patients [90] and hyaluronic acid (HA) 320 
seems involved in its regulation. Nevertheless, the interest of COX-2 is not 321 
definitively assessed as others studies revealed no modification of its expression 322 
[91]. On the other hand, at the transcript levels, TGF-β receptor, IGF-1 and insulin-323 
like growth factor binding protein-6 (IBP-6) appear to be downregulated [84]. 324 
Biomarkers in tears of TAO patients 325 
But, from our point of view, the most promising fluid for TAO in the future will be 326 
probably tears. Surprisingly, until now, tears and their clinical relevance have been 327 
poorly studied. With the non-invasive, easy and rapid collection of samples, tear-328 
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based approaches open up new routes for diagnostic methods and for understanding 329 
of both ocular and systemic diseases. Tears play a key role in the correct function 330 
and health of the eye. Tears are necessary for the lubrication of the eye surface that 331 
ensures the appropriate optical properties and for the nutrition and protection of 332 
surrounding tissues. Tears are secreted by lachrymal glands and contain 333 
electrolytes, nucleotides, lipids, metabolites and proteins. But these components can 334 
also be released from surrounding damaged tissues or by passive transport from 335 
blood. The production and composition of tears is therefore a dynamic system that 336 
depends on environmental factors, stimulus, infection or disease. Consequently, the 337 
ability to measure any subtle modification targeting one or several biomarkers in tear 338 
contents opens promising opportunities for screening not only ocular but also 339 
systemic diseases. 340 
The behaviour of the pro-inflammatory proteins in blood could be extrapolated to 341 
tears. A profile similar to that observed in the blood, can be highlighted in tears with a 342 
net increase of IL-1β, IL-6 and IL-17 in active compared to inactive TAO patients [62]. 343 
Another important actor of inflammation, Tumor necrosis factor (TNF)-α, has been 344 
measured only in tears. Its concentration is higher in inactive and active TAO patients 345 
than in control ones [62]. Moreover, two polymorphisms (-1031T/C and -863C/A) of 346 
TNF-α gene have been found in samples from a Japanese population with a dramatic 347 
increase in patients with Graves’ disease suffering from TAO in comparison to those 348 
without TAO. In addition, these polymorphisms seem associated to the severity of 349 
TAO [92]. Interleukin-7 has also been reported in tears and orbital fat and is 350 
suspected to changes according to the different phases of the disease [93]. Finally, 351 
using proteomics experiments, potential new candidates have been revealed such as 352 
Proline-rich-protein members (PROL1/PRP4) involved in the modulation of the 353 
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microflora of the eye, and presenting protective function [94, 95], or S100 calcium 354 
binding proteins (S100A8/S100A9) modulating inflammation and cell adhesion [94, 355 
95].   356 
 357 
Conclusions 358 
 The story of TAO biomarkers is just starting: efficient biomarkers used in routine for 359 
TAO have still to be discovered. Ideally, they will offer a new opportunity for 360 
improving early diagnosis, follow-up and treatment monitoring. Further, it could help 361 
to a better understanding of pathophysiology and permit new personalized-362 
therapeutic strategies. 363 
Nevertheless, to be a success story, biomarker discovery should carefully consider 364 
the best source of samples in relation to the clinical question and the characteristics 365 
of the TAO disease. In order to be extended on a larger scale and finally to the whole 366 
population, we strongly believe that a good source of biomarkers should take into 367 
account sample collection feasibility. Orbital fat or muscles, even if highly specific, 368 
will not be easy to obtain and their collection is an invasive method. They can be 369 
collected during a surgery of orbital decompression, which is possible only when the 370 
inflammation is calming down. It means also that such samples could not be 371 
extrapolated for basic diagnosis nor used as preventive tool. In these situations, 372 
common biofluids such as blood seem to be more appropriate for biomarker 373 
investigation. However, considering the past, whatever the disease, there has been 374 
little success in translating these findings into clinical applications. 375 
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More unusual samples including tears have recently emerged as new global source 376 
of biomarkers and could be promising and innovative clinical tests in TAO disease in 377 
the near future. Because tear sampling is a non-invasive and rapid method, tear-378 
based approaches open promising avenues for diagnostic method and will allow 379 
opportunities for deepening understanding of this challenging orbital disease. In 380 
addition, as a complex mixture, tears offer the possibility of discovering not only 381 
proteins but also RNAs, lipids, metabolites biomarkers that could interestingly 382 
complement the traditional clinical tools available for ophthalmologists.  383 
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Figures 666 
FIG. 1. Bilateral inflammatory Thyroid-Associated Orbitopathy with oedema and redness of 667 
eyes and lids 668 
 669 
FIG. 2. Left unilateral exophthalmos with limitation in upgaze and diplopia (double vision). 670 
 671 
